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Abstract
Background: In patients suffering from Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) disease
severity is assessed by Medical Research Counsil (MRC) Scale or Inflammatory Neuropathy Cause and Treatment
(INCAT) disability score. However, none of these methods is appropriate to objectively assess muscle weakness or to
detect very small subclinical changes. More objective and quantitative measures are needed in order to evaluate
treatment efficiency or to detect subclinical affection of upper limps for early diagnosis. The goal of our study was
to objectively quantify muscular weakness in CIDP patients with the non-invasive Quantitative Motor (Q-Motor) test
of Grip Force Assessment (QGFA) as well as the Involuntary Movement Assessment (QIMA) and to search for
differences between typical and atypical CIDP variants. In addition, we hypothesized that Q-Motor findings correlate
with disease severity scales such as MRC or INCAT score.
Methods: In this cross-sectional exploratory proof-of-concept study subjects with confirmed diagnosis of typical or
atypical CIDP were examined and compared to healthy controls (HC). For Q-Motor tests all subjects had to lift a
device (250 g and 500 g) equipped with an electromagnetic sensor that measured grip force (GF) and three-
dimensional changes in position and orientation. The measures “grip force variability” (GFV), “position index” (PI)
and “orientation index” (OI) were provided to assess involuntary movements due to muscular weakness.
Results: 33 patients with CIDP and 28 HC were included. All measures were significantly elevated in CIDP patients
for both devices in the right and left hand compared to healthy controls. Subgroup analysis revealed no differences
between typical and atypical CIDP variants. INCAT score only weakly correlated with OI and PI. However, there was
a stronger correlation between MRC and QIMA parameters in both hands.
Conclusion: Q-Motor assessments were capable to objectively assess muscular weakness in CIDP. In particular,
QIMA measures detected subclinical generalized muscle weakness even in patients with milder disability. Sensitivity
and rater-independence of Q-Motor assessments support a further exploration of QIMA measures as potential
endpoints for future clinical trials in CIDP.
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Background
Chronic inflammatory demyelinating polyneuropathy
(CIDP) is a rare autoimmune disorder of the periph-
eral nervous system leading to both proximal and
distal weakness of all extremities. Beside this typical
manifestation, there is a proportion of patients
suffering from atypical variants such as pure sensory
(sensory CIDP), distally acquired demyelinating
polyneuropathy (DADS) or asymmetric multifocal ac-
quired demyelinating sensory and motor polyneurop-
athy (MADSAM) neuropathies [1, 2]. CIDP is a
demyelinating disease leading to typical demyelinating
changes, which can be detected by nerve conduction
studies according to different established demyelinat-
ing criteria (European Federation of Neurological So-
cieties, EFNS; American Academy of Neurology,
AAN) and by MR-neurography or ultrasound. How-
ever, diagnosis may still be challenging due to the
great fraction of atypical variants for which no clear
diagnostic criteria exist [3]. Moreover, patients may
have suffered from the disease for long so that sec-
ondary axonal degeneration occurred. In these cases,
established paraclinical criteria may not be sufficient
alone. Accordingly, there is a remarkable rate of mis-
diagnosed CIDP, mainly atypical CIDP [4]. Recent
studies revealed the presence of autoantibodies to
paranodal junction proteins, such as neurofascin 155
and contactin 1 in a subpopulation of CIDP patients
[5]. There is evidence that the underlying mechanism
is distinct from those with classical macrophage-
induced demyelination [6].
Besides diagnostic challenges, the assessment of mus-
cular weakness is the most important treatment out-
come parameter. Based on recent studies there is an
increasing need to objectively assess the treatment effi-
cacy in order to avoid overtreatment and reduce high
treatment costs such as by intravenous immunoglobulins
(IVIG). The Medical Research Council Sum Score is
often applied in order to measure the muscle strength
on the level of impairment [7], whereas the INCAT
overall disability scale measures the disability resulting
from muscular weakness [8]. However, none of these
methods is appropriate to assess muscle weakness ob-
jectively and to detect even very small subclinical
changes.
Here, we hypothesized that muscular weakness in pa-
tients with CIDP can be objectively quantified with (1)
non-invasive quantitative motor (Q-Motor) assessment
of grip force and involuntary activity and (2) that patho-
logical findings correlate with disease severity as mea-
sured by the MRC and INCAT disability score. In
addition, we asked whether patients with atypical mani-
festation show subclinical signs of generalized muscle
weakness compared to healthy controls.
Methods
Patients
In this cross-sectional observational study patients
who met the diagnostic criteria for typical and atyp-
ical CIDP of the EFNS 2010 [9] were included in
order to objectively quantify muscular weakness with
non-invasive Q-Motor assessment of grip force and
involuntary activity. Patients were screened consecu-
tively between March and August 2013 in our out-
patient clinic of the Department of Neurology,
Charité University Medicine, Berlin, Germany. Data of
all CIDP patients was compared to a group of healthy
controls (HC) that was similar in age and sex (distri-
bution) to the patient group. HC had to meet the fol-
lowing criteria: Age ≥ 18 years, no other neurological
diseases, no other diseases affecting the musculoskel-
etal system, no cognitive deficits. Overall, 33 patients
with CIDP and 28 HC were included. Unlike recent
epidemiological data, numbers of recruited typical and
atypical CIDP patients were nearly identical for statis-
tical reasons [10]. There was no testing for NF155
and CNTN1 antibodies for patients with atypical
CIDP.
Clinical assessment
Patients were examined by the treating neurologist
(JK). Sociodemographics as well as current medication
were documented. We used the adjusted inflamma-
tory neuropathy cause and treatment (INCAT) dis-
ability score [8] and the Medical Research Council
(MRC) sum score [7] to assess the clinical status
within 2 months when clinically stable. For the MRC
the following muscles had been tested on both sides:
shoulder abduction, elbow flexion, wrist extension,
index finger extension, hip flexion, knee extension,
ankle dorsiflexion, extension of the big toe. For classi-
fication, we used CIDP disease activity status (CDAS)
[11], summarizing unstable active and improving sta-
tus as unstable stage, stabile active status and remis-
sion status as stable stage..
Quantitative motor assessment and data analysis
The Quantitative-Motor (Q-Motor) grip-and-lift task
(manumotography) providing data for “Quantitative
Grip Force Assessment” (QGFA) and “Quantitative
Involuntary Movement Assessment” (QIMA) was
performed as described earlier [12, 13]. Briefly, all sub-
jects were seated in an upright position. They were
then asked to grip and lift an instrument with two
force-torque sensors (Nano-40, ATI, Apex, NC), which
measured the grip (normal) and load (tangential) forces
of the thumb and index finger. The instrument’s weight
could be modified to 250 g (light) and 500 g (heavy). An
electromagnetic sensor (Fastrack, Polhemus, VT)
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constantly measured the instrument’s three-dimensional
position (x, y, z) and orientation (roll, pitch, yaw). The ob-
ject was held 10 cm adjacent to a marker for 15 s (static
holding phase). Patients performed five consecutive re-
corded trials with each object weight (light and heavy) and
with both hands.
The mean isometric grip force (GF) was calculated as
the average of the 5 repetitions during the static holding
phase. The amount of involuntary movement during the
static holding phase was assessed by recording changes
in position (x, y, z) and orientation (roll, pitch, yaw). In
order to assess the mean amount of involuntary move-
ments during the static phase, the means of the absolute
values of the derivatives of position (the x, y, and z chan-
nels) and of the orientation (roll, pitch, and yaw chan-
nels) were calculated and summed up to create a
position index (PI) and an orientation index (OI) [14].
For patients who were treated with infusions on a regu-
lar basis, Q-Motor tests were obtained in the middle of
an infusion interval in order to avoid end of dose effects.
All Q-Motor data was transferred to the Q-Motor
group at the George-Huntington-Institute, Muenster,
Germany, for blinded quality control and automated
computerized data analysis. Q-Motor outcomes were
then returned to the Charité for further analysis.
Statistical analysis
Statistical analyses were performed using Prism 6 soft-
ware (GraphPad, La Jolla, CA, USA). For group differ-
ences with regard to sex and treatment history Fisher’s
exact test was used. For normally distributed age, MRC
and INCAT score, unpaired t-test was used. QGFA and
QIMA parameters were tested by the two-tailed Mann-
Whitney and Kruskal-Wallis tests followed by Dunn’s
multiple comparison tests in two and more groups, re-
spectively. Level of significance was defined as p < 0.05
for all comparative tests. We did not perform correc-
tions for multiple comparisons as this was an explora-
tory study to explore proof-of-concept for quantitative
measurements for future research. To detect associa-
tions among Q-Motor measures (GF, PI, OI) and disease
severity as measured by the MRC-A score and INCAT
ODSS, we calculated Spearman coefficients.
Results
Patient characteristics
Altogether 33 CIDP patients were included, of these 22
(66.7%) fulfilled EFNS criteria of definite CIDP, 10
(30.3%) patients of probable CIDP and one patient with
possible CIDP (3%). Mean age was 64 years (median 65,
44–82) with no significant difference to control group
with a mean age of 59 years (median 60, 37–77). There
was a huge range regarding disease duration with a
minimum of one year and a maximum of 28 years
(Median 5, IQR 2–8). CIDP patients and controls did
not differ in sex, however atypical and typical patients
differed in sex significantly (see Table 1). 16 patients suf-
fered from typical CIDP (48.5%), and 17 patients from
atypical variants (51.5%). Of those with atypical variants,
10 patients suffered from DADS, 4 patients of sensory
CIDP and 3 of MADSAM (see Table 1). Patients with
typical CIDP had a higher INCAT ODSS compared to
atypical CIDP (p = 0.0004), which was also confirmed
for INCAT-A (INCAT Score of the arms) (p = 0.003).
Mean MRC–sum Score was 71.3 (SD 7.5; Minimum 48,
Maximum 80). However, MRC was only obtained from
22 patients. At the time of assessment, 19 (57.6%) pa-
tients had been treated with IVIG, 7 (21%) with gluco-
corticosteroids, none with plasma exchange (PE), 5
(15%) with other immunosuppressants (methotrexate,
azathioprine) and two received no treatment. The major-
ity of patients had been treated with glucocorticosteroids
sometime before. Only about 24% received plasma ex-
change in history. There was no difference between typ-
ical and atypical CIDP in terms of treatment procedures
(Table 1).
Quantitative grip force and involuntary movement
assessment in CIDP versus controls
The Q-Motor measures position index (PI), orientation
index (OI), and grip force variability (GFV) were signifi-
cantly increased in all CIDP patients compared to HC
for both weights in the left and also in the right hand
(Table 2, shown here only data for 500 g). No differences
between CIDP patients and HC were found for isometric
grip force (for details see Table 2).
Subgroups analysis of atypical versus typical CIDP
There was a statistical difference between typical, atyp-
ical CIDP and HC for the position index (PI) as well as
for orientation index (OI) (Kruskal-Wallis-test
p < 0.001). In post hoc analysis, PI as well as OI dif-
fered significantly between typical or atypical and HC
for both weight classes. However, no statistical differ-
ence could be detected between typical and atypical
groups itself in post hoc analysis (Table 3). Grip force
variability differed between CIDP subgroups and HC
for both weight classes with no difference between typ-
ical and atypical CIDP in post hoc analysis (Table 3 for
500 g, data not shown for 250 g). Patients with only
very mild affection of the arm function (INCAT-A ≤ 1,
n = 11 [36.7%]) as well as patients with higher arm
function disability (INCAT-A ≥ 2, n = 21 [63.3%])
showed significantly higher values for the PI as well as
for OI for both hands and weights compared to HC.
For grip force variability, only patients with INCAT-
A ≥ 2 showed significant increased values compared to
HC (Table 4 for 500 g, data not shown for 250 g).
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Correlation with INCAT ODSS and MRC
For all parameters that were significantly increased in CIDP
patients, we assessed the correlation with the INCAT and
MRC score. There was a weak correlation of GFV right
hand 250 g of all CIDP patients with INCAT score (Fig. 1a,
Spearman correlation index r = 0.37, p = 0.047) but not
with MRC (data not shown). OI of both hands
correlated by trend with INCAT (Fig. 1b shows for
the right hand, Spearman correlation index r = 0.37,
p = 0.05). There was also a moderate correlation of
OI with MRC-A of both hands for 500 g (Fig. 1c shows
right hand, for the left hand: r = − 0.43, p = 0.04) and for
the right hand with 250 g (r = − 0.47, p = 0.03). There was
no correlation of PI with INCAT or INCAT-A (data not
shown). However, we found a moderate correlation of
PI with MRC-A for the both hands (Fig. 1d shows
250 g right hand, for the left hand r = − 0.46; p = 0.04;
500 g r = − 0.47, p = 0.03).
Discussion
In this cross-sectional pilot study we investigated 33
CIDP patients compared to 28 HC using the Q-Motor
grip-and-lift task quantitatively assessing grip force and
involuntary movements. Aim of the study was to object-
ively assess muscle weakness and to detect even very
small subclinical changes in CIDP patients as well as to
search for differences between typical and atypical CIDP
variants. Involuntary movements parameters such as
Table 2 QGFA and QIMA parameters in CIDP versus controls
Q-Motor measure (unit) CIDP HC p-value n
CIDP/HC
Mean isometric grip force 500g_left hand (N) 10.86 (4.24) 9.1 (2.95) 0.1733 32/27
Mean isometric grip force 500g_right hand (N) 10.55 (3.95) 10.38 (4.05) 0.8881 31/28
Grip force variability 500g_ left hand (%) 6.97 (2.34) 5.40 (1.79) 0.0091 32/27
Grip force variability 500g_ right hand (%) 6.36 (1.96) 5.4 (2.38) 0.0085 31/28
Orientation index 500g_ left hand (°/s) 11.15 (6.09) 5.31 (4.13) < 0.0001 30/26
Orientationindex 500g_ right hand (°/s) 12.19 (7.74) 5.17 (3.36) < 0.0001 30/27
Position index 500g_ left hand (cm/s) 3.50 (1.51) 1.56 (0.83) < 0.0001 30/26
Position index 500g_ right hand (cm/s) 3.49 (1.65) 1.84 (1.47) < 0.0001 30/27
Table 1 Patient characteristics
CIDP all Typical CIDP Atypical CIDP HC
N total 33 16 17 28
sex, female (%) 12 (36,4) 10 (62,5) 2 (11,76)
P = 0.004
14 (50)
age (years), mean (SD) 64,18 (9,94) 62,50 (11,65) 65,75 (8,04) 59,54 (8,94)
median (range) 65 (44–82) 61 (44–82) 68 (52–80) 60 (37–77)
time since diagnosis, years, median (IQR) 5 (2–8) 7,5 (2.75–14.25) 3 (2–7) n.a.
CIDP disease activity status –stabile (%) 26 (85.8) 14 (87.5) 12 (70.6) n.a.
handedness, right handed (%) 31/32a (96.8) 16 (100) 16 (94) n.a.
INCAT ODSS, mean (SD) 3.4 (1.6) 4.4 (1.5) 2.4 (1.0)
P = 0.0002
n.a.
- arms 1.4 (0.75) 2.4 (1.0) 1.4 (0,96)
P = 0.003
n.a.
- legs 1.5 (0.9) 2 (1.0) 1.0 (0.001) n.a.
MRC, mean (SD) 71.5 (7.5) 68.9 (9.9) 73.0 (5.1) n.a.
treatment actually/ever (%)
- glucosteroids 7/24 (21/72.8) 5/13 (31/81) 2/11 (12/64) n.a.
- IVIg 19/33 (58/100) 10/16 (63/100) 9/17 (53/100) n.a.
- PE 0/8 (0/24.2) 0/4 (0/25) 0/4 (0/23) n.a.
- other 5/7 (15/21) 3/5 (19/31) 2/2 (12/12) n.a.
a missing data of one patient regarding handedness in CIDP group
Abbreviations: INCAT Inflammatory Neuropathy Cause and Treatment disability score, MRC Medical Research Counsil, SD Standard deviation, IQR Interquartile
range, IVIg Intravenous immunoglobulin, PE Plasma exchange
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Table 3 Subgroup analyses of typical and atypical CIDP
Parameter (Unit) Typical CIDP Atypical CIDP HC p-value Post hoc* No.**
Mean isometric grip force 500g_left hand (N) 9.34 (3.19) 12.20 (4.67) 9.1 (2.95) 0.0777 a) ns
b) ns
c) ns
15/17/27
Mean isometric grip force 500g_right hand (N) 9.40 (3.93) 11.70 (3.73) 10.38 (4.05) 0.1681 a) ns
b) ns
c) ns
16/16/28
Grip force variability 500g_ left hand (%) 6.94 (2.56) 6.99 (2.20) 5.40 (1.79) 0.0319 a) ns
b) ns
c) ns
15/17/27
Grip force variability 500g_ right hand (%) 7.16 (2.11) 5.56 (1.46) 5.4 (2.38) 0.0043 a) **
b) ns
c) ns
16/16/28
Orientation index
500g_ left hand (°/s)
13.24 (7.38) 9.54 (4.47) 5.31 (4.13) < 0.0001 a) ***
b) **
c) Ns
13/17/26
Orientation index 500g_ right hand (°/s) 13.45 (6.37) 11.08 (8.82) 5.17 (3.36) < 0.0001 a) ***
b) **
c) Ns
14/16/27
Position index 500g_ left hand (cm/s) 3.43 (1.35) 3.59 (1.65) 1.56 (0.83) < 0.0001 a) ***
b) ***
a) Ns
10/19/26
Position index 500g_ right hand (cm/s) 3.20 (1.91) 3.68 (1.56) 1.84 (1.47) < 0.0001 a) **
b) ***
a) Ns
10/19/27
* a) Typical CIDP vs. HC, b) Atypical CIDP vs. HC, c) Typical CIDP vs. Atypical CIDP
** typical/atypical/HC
Table 4 Subgroup analyses of mild and higher function disability
Parameter (Einheit) INCAT-A
≤ 1
INCAT-A
≥ 2
HC p-value Post hoc No.
Mean isometric grip force 500g_left hand (N) 11.44 (4.64) 10.64 (4.18) 9.1 (2.95) 0.3487 a) ns
b) ns
c) ns
11/20/27
Mean isometric grip force 500g_right hand (N) 10.28 (2.47) 10.77 (4.69) 10.38 (4.05) 0.9712 a) ns
b) ns
c) ns
11/20/28
Grip force variability 500g_left hand (%) 6.55 (2.18) 7.27 (2.47) 5.40 (1.79) 0.0223 a) ns
b) *
c) ns
11/20/27
Grip force variability 500g_right hand (%) 5.97 (2.35) 6.63 (1.77) 5.4 (2.38) 0.0123 a) ns
b) **
c) ns
11/20/28
Orientation index 500g_left hand (°/s) 10.24 (4.02) 11.78 (7.08) 5.31 (4.13) < 0.0001 a) **
b) ***
c) ns
10/19/26
Orientation index 500g_right hand (°/s) 10.46 (9.32) 13.17 (7.09) 5.17 (3.36) < 0.0001 a) *
b) ***
c) ns
10/19/27
Position index 500g_left hand (cm/s) 3.43 (1.35) 3.59 (1.65) 1.56 (0.83) < 0.0001 c) ***
d) ***
e) ns
10/19/26
Position index 500g_right hand (cm/s) 3.20 (1.91) 3.68 (1.56) 1.84 (1.47) < 0.0001 c) **
d) ***
e) ns
10/19/27
* a) INCAT ≤1 vs. HC, b) INCAT ≥2 vs. HC, c) INCAT ≤1 vs. INCAT ≥2
** INCAT-A ≤ 1/ INCAT ≥2/ HC
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GFV, OI and PI were significantly elevated in CIDP
compared to HC. Subgroup analysis revealed no dif-
ference between typical and atypical CIDP groups it-
self. Interestingly, patients with only very mild
affection of the arms (INCAT-A ≤ 1) showed the same
alterations of OI and PI compared to more disabled
patients (INCAT-A ≥ 2).
Beside sensory disturbance, the assessment of muscu-
lar weakness is essential in order to establish diagnosis
as well as evaluate treatment outcome.
So far, MRC and Martin’s Vigorimeter are established
endpoints applied in clinical routine. Grip strength can
be measured by using the Vigorimeter, a simple objective
tool that is easy to apply [15, 16]. However, it is only a
one-dimensional tool and thus may not be sensitive
enough to measure small subclinical changes in manual
coordination, for instance at disease onset or in atypical
variants.
The medical research council scale (MRC) also works
on the impairment level but has a great interrater vari-
ability and thus inherited imprecision. As a third out-
come measure, the INCAT disability scale assesses
disabling problems in daily arm and leg mobility and has
evolved as the most established primary outcome in
clinical trials since it was used in the large ICE trial of
CIDP patients [17, 18]. However, it mainly detects actual
disability and by definition is not sensitive to detect
smaller alterations.
The quantitative Q-Motor assessments were shown to
detect subclinical changes in patients with premanifest
Huntington’s disease and correlated well with disease se-
verity [13, 14, 19] and progression even 2 decades before
A B
C D
p
p
p
p
Fig. 1 Q-Motor involuntary movement measures correlations with CIDP disability scores. Correlations of grip force variability (a) position and
orientation index with INCAT disability score for the right hand heavy (a) and light weight (b). Correlations of orientation index of the right hand
for 500 g (c) as well as position index of the right hand (250 g) with MRC-A (D). p = p-value, r = Pearson correlation coefficient, solid line = fit line,
dotted line = 95% CI
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disease onset [20, 21]. Q-Motor measures detected drug
effects not seen in rater-dependent categorical clinical
scales in several multicenter clinical trials [22, 23]. Also,
Q-Motor testing has been proven as a meaningful tool
in order to measure muscular weakness in myasthenia
gravis [24].
In the present study we show significantly elevated
QIMA parameters in CIDP compared to HC. Sub-
group analysis showed elevated OI and PI in atypical
and typical CIDP compared with HC with no differ-
ence between both patient groups suggesting a good
applicability also for atypical variants. Although the
clinical picture differs markedly between CIDP sub-
groups, no differentiation has been performed in pub-
lished studies [16, 18] when using the INCAT score
or Martin vigorimeter. QIMA parameters may be a
meaningful tool in order to quantify muscular weak-
ness also in atypical variants, which needs to be in-
vestigated in a larger multicenter study. In contrast to
OI and PI, mean grip force did not differ significantly
in typical or atypical CIDP from HC. We therefore
concluded that involuntary movement parameters
might be more sensitive and thus more suitable in
order to detect even small changes in muscular weak-
ness. Accordingly, stratification in patients with only
mild affection of arm function (INCAT-A ≤ 1) showed
significantly higher values for the PI as well as for OI
for both hands and weights compared to HC.
In particular, patients with atypical manifestation are
misdiagnosed very frequently in almost 50% of all cases
[4] based on missing validated diagnostic criteria which
have only very recently described in more detail [10].
This leads to unnecessary and costly treatment; a recent
study reported that only 7 of 65 patients, i.e. 11%, receiv-
ing long-termly intravenous immunoglobulins actually
fulfilled the EFNS diagnostic criteria of CIDP [25].
Application of objective and sensitive assessments of
symptom severity and treatment efficacy may help to re-
duce misdiagnosis and overtreatment.
We acknowledge several limitations of this study.
Although the sample size of 33 CIDP patients is com-
paratively large considering that CIDP is an orphan
disease it is still too small to establish QIMA parame-
ters as diagnostic and/or efficacy parameters in CIDP
subgroups. This would need further confirmatory
studies. MRC hasbeen obtained only from 22 patients.
However, despite the limited number of MRC mea-
surements, correlation with QIMA parameters
reached statistically significance. In addition, grip
strength parameters by Martin vigorimeter or Jamar
[16, 26] have not been obtained and should be in-
cluded in a further larger cohort trial.
Recently, Knak et al. showed that grip strength is less
responsive to detect improvements after treatment than
isokinetic dynamometry at ankles in a retrospective
study. The authors concluded that grip strength as mea-
sured by JAMAR dynamometer does not seem to be an
appropriate surrogate parameter of overall muscle
strength and should be combined with isokinetic mea-
surements of the lower limbs [27]. In the present study,
we did not search for treatment efficacy parameters.
However, in order to obtain appropriate overall muscle
strength additional strength parameters of the lower
limbs such as isokinetic measurements or foot tapping
by Q-Motor may have to amended. Furthermore, we did
not perform corrections for multiple comparisons, as
this was an exploratory proof-of-concept study. How-
ever, the changes in OI and PI were robust and consist-
ent, supporting a likely biological relevance of our
findings. In addition, almost all patients had a stable dis-
ease activity status, i.e. they were stable under treatment
or in remission. Measuring treatment naïve patients in
larger cohort trials would probably enhance the ob-
served effects.
Conclusions
Q-Motor tests may be useful to objectively assess mus-
cular weakness in CIDP. The observations of our study
encourage further exploration in larger cohort trials. In
particular, QIMA parameters seem to be suitable to de-
tect subclinical generalized muscle weakness in patients
with milder disability and/or atypical phenotype. There-
fore, they might be a sensitive and reliable endpoint in
future CIDP trials and support data-driven, unbiased de-
cision making in clinical development of novel therapies.
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